Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

LEXX

Lexaria Bioscience Corp

Apr 15 • 04:00PM ET

1.99

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • Canada • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	8.67%	Shs Outstand	12.89M	Perf Week	-32.77%
Market Cap	25.65M	Forward P/E	-	EPS next Y	-0.49	Insider Trans	0.00%	Shs Float	11.77M	Perf Month	-48.31%
Income	-6.89M	PEG	-	EPS next Q	-0.10	Inst Own	9.50%	Short Float	4.17%	Perf Quarter	31.79%
Sales	0.34M	P/S	75.44	EPS this Y	47.03%	Inst Trans	9.21%	Short Ratio	1.00	Perf Half Y	103.08%
Book/sh	0.53	P/B	3.78	EPS next Y	7.48%	ROA	-95.89%	Short Interest	0.49M	Perf Year	-13.85%
Cash/sh	0.37	P/C	5.36	EPS next 5Y	-	ROE	-101.53%	52W Range	0.65 - 6.85	Perf YTD	59.20%
Dividend Est.	-	P/FCF	-	EPS past 5Y	18.43%	ROI	-103.76%	52W High	-70.95%	Beta	1.06
Dividend TTM	-	Quick Ratio	66.29	Sales past 5Y	9.26%	Gross Margin	42.24%	52W Low	206.72%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	66.29	EPS Y/Y TTM	6.34%	Oper. Margin	-2024.38%	RSI (14)	32.42	Volatility	13.49% 13.56%
Employees	5	Debt/Eq	0.02	Sales Y/Y TTM	94.44%	Profit Margin	-2022.66%	Recom	1.00	Target Price	11.00
Option/Short	No / Yes	LT Debt/Eq	0.02	EPS Q/Q	79.57%	Payout	-	Rel Volume	0.00	Prev Close	1.99
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	42.89%	Earnings	-	Avg Volume	488.87K	Price	1.99
SMA20	-38.36%	SMA50	-35.62%	SMA200	21.71%	Trades		Volume	0	Change	0.00%

Apr-09-24 09:52PM	LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024 (InvestorPlace) -8.78%
Apr-02-24 09:00AM	Lexaria Awarded New Patents (ACCESSWIRE)
Mar-21-24 09:20AM	Lexaria to Present at The LD Micro Invitational XIV (Newsfile) -7.03%
Mar-14-24 09:20AM	Lexaria Appoints Nelson Cabatuan as Chief Financial Officer (ACCESSWIRE) -12.50%
Mar-07-24 09:05AM	Lexaria Awards Contract For Next GLP-1 Human Pilot Study (ACCESSWIRE) +11.61%
09:05AM	Loading…
Mar-05-24 09:05AM	Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 (ACCESSWIRE) +12.67%
Mar-04-24 09:15AM	7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study (ACCESSWIRE)
Mar-01-24 08:20AM	Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE) -15.36%
Feb-16-24 04:05PM	Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.32%
Feb-15-24 08:00AM	Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.23%
Jan-30-24 08:45AM	Lexaria's Submits Investigational New Drug Application (ACCESSWIRE)
Jan-24-24 08:45AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-22-24 08:51AM	LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024 (InvestorPlace)
Jan-16-24 09:10AM	Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program (ACCESSWIRE)
Jan-11-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream (GlobeNewswire) +5.56%
08:30AM	Loading…
Jan-10-24 08:30AM	GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons (PR Newswire)
Jan-09-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform (GlobeNewswire)
Jan-08-24 08:30AM	Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs (PR Newswire)
Jan-04-24 09:05AM	Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide (ACCESSWIRE) +6.92%
Dec-07-23 09:20AM	Lexaria's Investigational New Drug Application Filing Update (ACCESSWIRE)
Nov-28-23 09:10AM	Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study (ACCESSWIRE)
Nov-27-23 09:05AM	Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study (ACCESSWIRE) +24.43%
Nov-01-23 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space (GlobeNewswire) +5.07%
08:30AM	Get Ready for Next Generation of Diabetes, Weight-Management Drugs (PR Newswire)
Oct-31-23 08:31AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs (GlobeNewswire)
Oct-30-23 09:30AM	Can Diabetes, Weight-Loss Drugs Get Even Better (PR Newswire) +14.66%
Oct-13-23 09:05AM	Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn (ACCESSWIRE) -6.61%
Oct-12-23 09:10AM	Lexaria Granted Two New Patents in Canada (ACCESSWIRE)
Sep-29-23 08:00AM	Lexaria Announces Pricing of $1.6 Million Registered Direct Offering (ACCESSWIRE)
Sep-21-23 09:10AM	Lexaria to Evaluate Impact of DehydraTECH on Oral Performance of GLP-1 drugs used in products such as Ozempic, Wegovy and Rybelsus, Alone or Together with DehydraTECH-CBD (ACCESSWIRE)
09:20AM	Loading…
Aug-30-23 09:20AM	Lexaria Provides Update on Investigational New Drug Application Progress (ACCESSWIRE)
Aug-28-23 09:02AM	LEXX: 3Q:23 Financial Results & Corporate Updates (Zacks)
Aug-23-23 11:12AM	Lexaria Bioscience Corp: A Comprehensive Stock Price Change Analysis (GuruFocus.com)
Aug-09-23 09:15AM	Lexaria's DehydraTECH-Nicotine Faster than ZYN and on! (ACCESSWIRE) +6.81%
Aug-02-23 09:10AM	Lexarias Plans to Study Weight Loss and Diabetes Control in a Human Clinical Study with DehydraTECH-CBD (ACCESSWIRE)
Jul-28-23 09:10AM	Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study (ACCESSWIRE)
Jul-19-23 09:05AM	Lexaria Granted Strategically Important New US Patent For DehydraTECH-Nicotine Including Oral Pouch Products (ACCESSWIRE)
Jun-26-23 07:47AM	LEXX: A Little Bit of Everything (Zacks Small Cap Research)
Jun-22-23 09:25AM	Lexaria's Groundbreaking Research into DehydraTECH-CBD Published in International Journal of Molecular Science (ACCESSWIRE) +8.51%
Jun-20-23 09:05AM	Lexaria Receives New Patents (ACCESSWIRE)
Jun-16-23 09:10AM	Lexarias DehydraTECH-CBD Lowers Blood Glucose Levels in Diabetes Animal Study (ACCESSWIRE)
Jun-12-23 09:20AM	Lexaria Appoints New Chief Financial Officer (ACCESSWIRE)
May-23-23 09:05AM	Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers (ACCESSWIRE) +13.21%
May-18-23 04:22PM	Study Shows Significant Improvements In Peak Bloodstream Estradiol Delivery Using Lexaria's DehydraTECH (Benzinga) +19.60%
09:05AM	Lexaria's Hormone Study Shows Significant Enhancement in Oral Estradiol Delivery (ACCESSWIRE)
May-11-23 01:45PM	Lexaria Bioscience Announces Closing of $2.0 Million Public Offering (ACCESSWIRE)
09:00AM	cGMP Manufacturing Complete for Lexaria's Upcoming U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE)
May-10-23 10:15AM	Lexaria Announces 2023 Annual Meeting Results (ACCESSWIRE)
May-08-23 08:35PM	Lexaria Bioscience Announces Pricing of $2.0 Million Public Offering (ACCESSWIRE) -21.76%
09:05AM	Lexarias Human Clinical Nicotine Study Completes Dosing as Planned (ACCESSWIRE)
Apr-24-23 09:00AM	Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study (ACCESSWIRE)
Apr-20-23 09:00AM	Lexaria is Receiving Four New Patents (ACCESSWIRE)
05:40AM	LEXX: DehydraTECH CBD May Offer New Mechanism of Action (Zacks Small Cap Research)
Mar-07-23 05:54AM	Is Lexaria Bioscience (NASDAQ:LEXX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Mar-02-23 08:45AM	Lexaria's DehydraTECH-CBD Diabetes Study Demonstrates Weight Loss, Improved Triglyceride and Cholesterol Levels (ACCESSWIRE)
Feb-21-23 02:41PM	Lexaria Discovers Potential Novel Mechanism From Hypertension Study Of Processed CBD (Benzinga)
09:00AM	Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4 (ACCESSWIRE)
Jan-31-23 08:30AM	Lexaria Bioscience: Charting a Path to Commercial Success (NewMediaWire)
Jan-23-23 08:45AM	Former President of GW Pharmaceuticals USA Joins Lexaria Bioscience as Strategic Advisor (ACCESSWIRE)
Jan-17-23 08:33AM	LEXX: DehydraTECH: Developing Diabetes and Dementia (Zacks Small Cap Research)
Jan-13-23 04:05PM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Dec-29-22 09:00AM	Lexaria Receives First Granted Patent in Canada (ACCESSWIRE)
Dec-21-22 09:00AM	Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels (ACCESSWIRE) +5.60%
Dec-20-22 12:35PM	Lexarias Human Oral Nicotine Study Begins Dosing (ACCESSWIRE)
Nov-30-22 05:24AM	Lexaria Bioscience Full Year 2022 Earnings: Misses Expectations (Simply Wall St.) +9.63%
Nov-29-22 08:50AM	Lexarias DehydraTECH-CBD(TM) Enhances Performance Compared to Epidiolex(R) in Seizure Study Program (ACCESSWIRE) +10.66%
08:31AM	Lexaria's DehydraTECH-CBD Enhances Performance Compared to Epidiolex in Seizure Study Program (News Direct)
Nov-21-22 09:19AM	Lexaria Bioscience Turns Focus to Dementia and Diabetes with New Studies (Newsfile)
Nov-10-22 09:20AM	Lexaria Examining Potential Therapeutic Use of DehydraTECH-CBD in Dementia (ACCESSWIRE)
Nov-08-22 09:10AM	Lexaria Starts Study Evaluating the Effect of DehydraTECH-CBD on Diabetes (ACCESSWIRE)
Nov-01-22 09:25AM	Lexaria Receives Independent Review Board Approval for its Upcoming Human Oral Nicotine Study (ACCESSWIRE)
Oct-31-22 05:26AM	LEXX: DehydraTECH CBD HYPER-H21-4 Results (Zacks Small Cap Research)
Oct-27-22 08:45AM	Lexaria's Human Clinical Hypertension Study a Success (ACCESSWIRE) +5.80%
Sep-20-22 08:30AM	Lexaria Bioscience: Taking Aim at the $28 Billion Hypertension Market; Human Clinical Study Yields 'Remarkable' Results (Newsfile)
Sep-02-22 09:15AM	Lexaria Welcomes Dr. Catherine Turkel to its Board of Directors (ACCESSWIRE)
Aug-31-22 09:05AM	Lexaria Receives New Patent in Mexico (ACCESSWIRE)
Aug-11-22 09:15AM	Lexaria Discusses Valuation Metrics for Biotech Industry (ACCESSWIRE) +12.77%
08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Focused on Filling Need for Hypertension Treatment Solution (GlobeNewswire)
Aug-10-22 10:36AM	Lexaria Bioscience' Tech Processed Cannabidiol Receives Positive FDA Feedback For Hypertension (Benzinga)
08:15AM	Lexaria Announces Positive Feedback from Pre-IND Meeting with FDA on DehydraTECH-CBD for Hypertension (ACCESSWIRE)
Aug-09-22 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Developing Powerful Tech to Treat Hypertension (GlobeNewswire)
Aug-03-22 09:45AM	LEXX: Put Your Drinks Up! Four Deals Signed in June (Zacks Small Cap Research)
Jul-27-22 09:10AM	Lexaria's DehydraTECH-CBD Hypertension Study HYPER-H21-4 Dosing Complete with No Serious Adverse Events (ACCESSWIRE)
Jul-26-22 09:05AM	Lexaria's Licensee Premier Wellness Science Co., Ltd. Launches New Brand in Preparation to Deploy DehydraTECH CBD Products in Japan (ACCESSWIRE)
Jul-14-22 09:10AM	Lexaria To Receive Third Patent Granted in Japan; Submits FDA Filing (ACCESSWIRE)
Jul-13-22 09:05AM	Lexaria's Human Nicotine Study Nearing Start Date (ACCESSWIRE)
Jul-07-22 09:05AM	Cannadips is Expanding Internationally, Leveraging Lexaria's DehydraTECH (ACCESSWIRE)
Jun-21-22 09:00AM	Lexaria Signs Manufacturing and License Agreements with BevNology (ACCESSWIRE) +18.88%
Jun-08-22 09:00AM	Lexaria Grants License to AnodGen Bioceuticals (ACCESSWIRE)
08:22AM	LEXX: Global Deals Take Center Stage (Zacks Small Cap Research)
Jun-06-22 09:15AM	Lexaria Files Pre-IND Meeting Request Letter with U.S. FDA (ACCESSWIRE)
Jun-03-22 02:00AM	Lexaria Grants Exclusive License to Premier Wellness Science Co., Ltd. for Strategic and Long-Term Partnership in the Japanese Market (ACCESSWIRE)
Jun-02-22 09:05AM	Lexaria Grants License to Valcon Medical for the European Market (ACCESSWIRE) +8.17%
Jun-01-22 09:00AM	Lexaria Announces 2022 Annual Meeting Results (ACCESSWIRE)
May-26-22 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Stands as Global Leader in Delivery Tech Space (GlobeNewswire)
May-25-22 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Breakthrough Delivery Tech in Hot Nicotine Space (GlobeNewswire)
Apr-21-22 10:39AM	Lexaria Posied To Receive US Patent For DehydraTECH To Deliver Antiviral Drugs (Benzinga)
09:05AM	Lexaria Granted Patent for Use of DehydraTECH to Deliver Antiviral Drugs (ACCESSWIRE)
Apr-19-22 11:38AM	LEXX: Hypertension Results Raise Stakes (Zacks Small Cap Research)
09:05AM	Lexaria Commences Multi-Week Human Clinical Hypertension Study (ACCESSWIRE)

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LEXX

Lexaria Bioscience Corp

Upgrade your FINVIZ experience